低密度脂蛋白颗粒聚集易感性取决于脂质组、可改变并与未来心血管死亡相关
研究开发了体外重组人分泌型鞘磷脂酶诱导脂解评估LDL聚集易感性的新方法,在已确诊冠心病患者中发现聚集易感性高的LDL可独立于传统危险因素预测未来心血管死亡,且该易感性与LDL脂质组成相关,可通过PCSK9抑制或健康饮食等干预改变。
要点
- LDL聚集易感性是独立于传统危险因素的心血管死亡预测因素
- 聚集易感LDL含更多鞘脂、更少磷脂酰胆碱
- PCSK9抑制或健康饮食可降低LDL聚集易感性
核心结论
- LDL颗粒对聚集的易感性是人类动脉粥样硬化性心血管疾病进展的一种新的可测量且可改变的因素。
研究设计与样本
- 研究开发了可重复的新方法,用重组人分泌型鞘磷脂酶体外诱导脂解评估LDL聚集易感性。
- 在已确诊冠心病患者中分析LDL聚集易感性与未来心血管死亡的关系。
- 在动物模型中实施三种干预改变LDL组成并观察对聚集易感性和动脉粥样硬化的影响。
- 在人类中通过PCSK9抑制或健康饮食诱导相似的组成变化并评估LDL聚集易感性。
主要发现
- 在已确诊冠心病患者中,聚集易感LDL的存在可预测未来心血管死亡,且独立于传统危险因素。
- 聚集易感LDL比聚集抵抗LDL含更多鞘脂和更少磷脂酰胆碱。
- 动物模型中三种理性改变LDL组成的干预降低了聚集易感性并减缓动脉粥样硬化。
- 人类中PCSK9抑制或健康饮食诱导的相似组成变化也降低了LDL聚集易感性。
- 体外聚集LDL可激活巨噬细胞和T细胞,这两种细胞参与斑块进展和破裂。
临床怎么用
- LDL聚集易感性可作为评估ASCVD进展的新指标,但需进一步标准化检测方法。
- 通过PCSK9抑制或健康饮食改变LDL脂质组成可能降低聚集易感性,从而减缓动脉粥样硬化。
局限性
- 研究未报告样本量、具体效应值及置信区间等定量数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Low-density lipoprotein (LDL) particles cause atherosclerotic cardiovascular disease (ASCVD) through their retention, modification, and accumulation within the arterial intima. High plasma concentrations of LDL drive this disease, but LDL quality may also contribute. Here, we focused on the intrinsic propensity of LDL to aggregate upon modification. We examined whether inter-individual differences in this quality are linked with LDL lipid composition and coronary artery disease (CAD) death, and basic mechanisms for plaque growth and destabilization. METHODS AND RESULTS: We developed a novel, reproducible method to assess the susceptibility of LDL particles to aggregate during lipolysis induced ex vivo by human recombinant secretory sphingomyelinase. Among patients with an established CAD, we found that the presence of aggregation-prone LDL was predictive of future cardiovascular deaths, independently of conventional risk factors. Aggregation-prone LDL contained more sphingolipids and less phosphatidylcholines than did aggregation-resistant LDL. Three interventions in animal models to rationally alter LDL composition lowered its susceptibility to aggregate and slowed atherosclerosis. Similar compositional changes induced in humans by PCSK9 inhibition or healthy diet also lowered LDL aggregation susceptibility. Aggregated LDL in vitro activated macrophages and T cells, two key cell types involved in plaque progression and rupture. CONCLUSION: Our results identify the susceptibility of LDL to aggregate as a novel measurable and modifiable factor in the progression of human ASCVD.
引用
- Ruuth M, Nguyen SD, Vihervaara T, et al. Susceptibility of low-density lipoprotein particles to aggregate depends on particle lipidome, is modifiable, and associates with future cardiovascular deaths. Eur Heart J. 2018. PMID: 29982602. doi:10.1093/eurheartj/ehy319
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。